IGF-I therapy in growth disorders

Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Patients with GH insensitivity, typically resulting from mutations affecting the GH receptor (GHR), GHR signaling cascade, or the IGF-I gene, are, generally, unresponsive to GH therapy. Beginning in the 1990s, clinical trials of IGF-I administration in such patients demonstrated both short- and long-term efficacy, although not to the degree observed with GH treatment of naïve GH-deficient patients. Adverse effects, including hypoglycemia, lymphoid overgrowth, benign intracranial pressure, and coarsening of facial features, have been observed, but, in general, have proven to be transient. As interest in the potential efficacy of IGF-I treatment for children currently labeled as idiopathic short stature increases, it will be important to have controlled clinical trials of GH, versus IGF-I versus combination, GH+IGF-I.

Original languageEnglish (US)
JournalEuropean Journal of Endocrinology
Volume157
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 2007

Fingerprint

Growth Disorders
Insulin-Like Growth Factor I
Therapeutics
Controlled Clinical Trials
Intracranial Pressure
Hypoglycemia
Clinical Trials
Mutation
Genes

ASJC Scopus subject areas

  • Endocrinology

Cite this

IGF-I therapy in growth disorders. / Rosenfeld, Ronald (Ron).

In: European Journal of Endocrinology, Vol. 157, No. SUPPL. 1, 08.2007.

Research output: Contribution to journalArticle

Rosenfeld, Ronald (Ron). / IGF-I therapy in growth disorders. In: European Journal of Endocrinology. 2007 ; Vol. 157, No. SUPPL. 1.
@article{626ddea282f640dbb442e6e20d4f11ac,
title = "IGF-I therapy in growth disorders",
abstract = "Patients with GH insensitivity, typically resulting from mutations affecting the GH receptor (GHR), GHR signaling cascade, or the IGF-I gene, are, generally, unresponsive to GH therapy. Beginning in the 1990s, clinical trials of IGF-I administration in such patients demonstrated both short- and long-term efficacy, although not to the degree observed with GH treatment of na{\"i}ve GH-deficient patients. Adverse effects, including hypoglycemia, lymphoid overgrowth, benign intracranial pressure, and coarsening of facial features, have been observed, but, in general, have proven to be transient. As interest in the potential efficacy of IGF-I treatment for children currently labeled as idiopathic short stature increases, it will be important to have controlled clinical trials of GH, versus IGF-I versus combination, GH+IGF-I.",
author = "Rosenfeld, {Ronald (Ron)}",
year = "2007",
month = "8",
doi = "10.1530/EJE-07-0187",
language = "English (US)",
volume = "157",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - IGF-I therapy in growth disorders

AU - Rosenfeld, Ronald (Ron)

PY - 2007/8

Y1 - 2007/8

N2 - Patients with GH insensitivity, typically resulting from mutations affecting the GH receptor (GHR), GHR signaling cascade, or the IGF-I gene, are, generally, unresponsive to GH therapy. Beginning in the 1990s, clinical trials of IGF-I administration in such patients demonstrated both short- and long-term efficacy, although not to the degree observed with GH treatment of naïve GH-deficient patients. Adverse effects, including hypoglycemia, lymphoid overgrowth, benign intracranial pressure, and coarsening of facial features, have been observed, but, in general, have proven to be transient. As interest in the potential efficacy of IGF-I treatment for children currently labeled as idiopathic short stature increases, it will be important to have controlled clinical trials of GH, versus IGF-I versus combination, GH+IGF-I.

AB - Patients with GH insensitivity, typically resulting from mutations affecting the GH receptor (GHR), GHR signaling cascade, or the IGF-I gene, are, generally, unresponsive to GH therapy. Beginning in the 1990s, clinical trials of IGF-I administration in such patients demonstrated both short- and long-term efficacy, although not to the degree observed with GH treatment of naïve GH-deficient patients. Adverse effects, including hypoglycemia, lymphoid overgrowth, benign intracranial pressure, and coarsening of facial features, have been observed, but, in general, have proven to be transient. As interest in the potential efficacy of IGF-I treatment for children currently labeled as idiopathic short stature increases, it will be important to have controlled clinical trials of GH, versus IGF-I versus combination, GH+IGF-I.

UR - http://www.scopus.com/inward/record.url?scp=34548836852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548836852&partnerID=8YFLogxK

U2 - 10.1530/EJE-07-0187

DO - 10.1530/EJE-07-0187

M3 - Article

VL - 157

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - SUPPL. 1

ER -